Mereo BioPharma Group plc Block Listing Application (1223S)

TIDMMPH

RNS Number : 1223S

Mereo BioPharma Group plc

06 July 2020

Mereo BioPharma Group plc

(" Mereo " or the "Company")

Block Listing Application

London and Redwood City, Calif., July 6, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that an application has been made to the London Stock Exchange for a block listing of 60,000,000 ordinary shares of GBP0.003 each in the Company ("Ordinary Shares").

These Ordinary Shares will be issued from time to time in order to satisfy the requirement to allot shares pursuant to the exercise of warrants to subscribe for new Ordinary Shares ("Warrants") and the conversion of unsecured convertible loan notes due 2023 into new Ordinary Shares ("Notes"). The Warrants and Notes were issued as part of the recently completed fundraising announced on 4 June 2020.

It is expected that admission will become effective on 9 July 2020. The Ordinary Shares under the block listing will rank pari passu with the Company's existing Ordinary Shares.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo's strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to $300M in milestone payments. Mereo's lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD"). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study.

Mereo BioPharma Contacts:

 
Mereo                                          +44 (0)333 023 7300 
Denise Scots-Knight, Chief Executive Officer 
 
Cantor Fitzgerald Europe (Nominated Adviser 
 and Broker to Mereo )                         +44 (0)20 7894 7000 
Phil Davies 
Will Goode 
 
Burns McClellan (US Public Relations Adviser 
 to Mereo)                                     +01 (0) 212 213 0006 
Lisa Burns 
Steve Klass 
 
FTI Consulting (UK Public Relations Adviser 
 to Mereo )                                     +44 (0)20 3727 1000 
Simon Conway 
Ciara Martin 
 
Investors                                      investors@mereobiopharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ALSFIFVTDLIRIII

(END) Dow Jones Newswires

July 06, 2020 04:34 ET (08:34 GMT)

Mereo Biopharma (LSE:MPH)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025